Early Access — free while we kick the tires
EdgarHawk

Walker Luke Nathaniel

Director

Director
1 filing analyzed · 1 company · Latest 2025-02-04

Companies

Company Buys Sells Direction
Zentalis Pharmaceuticals, Inc. ZNTL 1 0 Net buying

Activity

February 2025
Buy
14,200 shares
$24,966
Significance 7/10

Director Walker bought 14.2K shares at $1.76 (now $1.63, -49.7% in 30d); cluster buy pattern with 2 insiders in 14 days; unprofitable company.

Walker Luke Nathaniel acquired 14,200 shares at $1.76 on 2025-01-31, raising his holdings to 86,681 shares, a 19.6% increase from prior holdings of 72,481 shares. This purchase occurred in a cluster pattern where 2 other insiders also bought within the past 14 days, suggesting coordinated management interest despite the company's deteriorating valuation. However, the macroscopic context is challenging: the stock is trading at $1.63, down 49.7% in the past 30 days and 57.6% in 90 days—now 89.9% below its 52-week high of $16.13. Zentalis is unprofitable with quarterly revenue of $0.00 and a net loss of $40.2M over the most recent full fiscal year, creating significant execution risk. The simultaneous cluster activity and steep valuation collapse merit investigation into whether insiders are positioned for stabilization or whether the buy pattern reflects access to material information not yet public.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access